Stephen V. Liu, MD, Discussed the Importance of Testing for Oncogenic Drivers in Frontline NSCLC


CancerNetwork® sat down with Stephen V. Liu, MD, at the 2021 American Society of Clinical Oncology Annual Meeting to talk about pralsetinib for patients with non–small cell lung cancer harboring RET fusions and adequate biomarker testing in the frontline.

At the 2021 American Society of Clinical Oncology Annual Meeting, CancerNetwork® spoke with Stephen V. Liu, MD, regarding his poster presentation of the phase 1/2 ARROW trial (NCT03037385) featuring pralsetinib (Gavreto) in patients with RET fusion–positive non–small cell lung cancer (NSCLC) who are receiving treatment in the frontline setting.

In addition to efficacy data for pralsetinib in this indication, the data served to inform clinicians about the importance of genomic testing in the first line for patients with NSCLC, Liu said.


When we see these high response rates—88% [with pralsetinib]—for relatively rare subsets of lung cancer, it reminds us that it is increasingly critical to be sure we’re testing patients’ cancers appropriately and thoroughly. Now we have drugs that are real difference makers, not just in this subset [with RET fusions], but many others. It’s only possible if we identify the mutations and fusions so we can afford patients those benefits. I think it would be tragic for this option to go unused for someone with RET fusion–positive lung cancer because the cancer hadn’t been adequately tested.

It’s more important these days because the alternative therapy is immunotherapy in some form or another, which is not really an effective treatment for RET fusion­–positive lung cancer. If we miss this biomarker, if we do incomplete testing, or skip some markers, we missed the opportunity to give a well-tolerated, extremely effective oral therapy. Instead, we give an expensive immunotherapy agent that is very unlikely to work. It’s very important we find these alterations—if we’re not testing for [RET fusions then we] can’t find them. If you’re not doing complete testing, then it really is difficult to give the proper treatment for patients with lung cancer.


Curigliano G, Gainor JF, Greisinger F, et al. Safety and efficacy of pralsetinib in patients with advanced RET fusion-positive non-small cell lung cancer: Update from the ARROW trial. J Clin Oncol. 2021;39(suppl 15):9089. doi:10.1200/JCO.2021.39.15_suppl.9089

Related Videos
Common adverse effects following treatment with lenvatinib plus pembrolizumab in the phase 3 CLEAR study include diarrhea, hypertension, and fatigue, according to Thomas E. Hutson, DO, PharmD, FACP.
Lenvatinib in combination with pembrolizumab appears to raise no new safety signals in patients with advanced clear cell renal cell carcinoma after 4 years of follow-up in the phase 3 CLEAR study.
According to Thomas E. Hutson, DO, PharmD, FACP, 4-year follow-up data from the phase 3 CLEAR study confirm the maintained benefits of lenvatinib plus pembrolizumab in patients with advanced renal cell carcinoma.
Findings from the phase 3 MIRASOL trial support mirvetuximab soravtansine as a standard treatment option for platinum-resistant ovarian cancer, according to Ritu Salani, MD.
Rana R. McKay, MD discusses presentations of interest that were presented at the 2023 Kidney Cancer Research Summit, including a discussion on how PET imaging may identify which patients with renal cell carcinoma may respond to immunotherapy.
A better understanding of tumor biology may be necessary for identifying novel non-immunotherapy–based therapeutic strategies for patients with renal cell carcinoma, according to Rana R. McKay, MD.
Probiotics and other agents targeting fatty acid oxidation are also under evaluation as treatment options for patients with renal cell carcinoma, according to Rana R. McKay, MD.
Other angiogenic agents are also under investigation in renal cell carcinoma, according to Rana McKay, MD, who indicates it will be interesting to see how they compare with belzutifan.
Expert on NSCLC
Related Content